The antioxidant effect of Echinacea angustifolia and Echinacea purpurea in rat colitis model induced by acetic acid.

BACKGROUND: Ulcerative colitis is a chronic inflammatory condition of the colon, and reactive oxidative metabolites (ROMs) play an important role in its pathogenesis. Alternative therapies such as herbal remedies are increasingly being used in the treatment of ulcerative colitis for better clinical outcome of ulcerative colitis and less adverse effects. Echinacea has many features including antioxidant and wound-healing properties. Hence, the present study was undertaken to evaluate the protective effect of Echinacea spp. on experimental colitis model induced by acetic acid in Wistar albino rats. METHODS: Acute colitis was induced by intrarectal administration of acetic acid. Rats were divided into four groups, namely control, Echinacea-administered, Echinacea-administered-colitis and colitis. Malondialdehyde and total antioxidant status were assayed in tissue samples. Histopathological evaluation was also performed. RESULTS: Macroscopic and microscopic scores were significantly higher in colitis group compared to control, Echinacea and Echinacea-colitis groups (p < 0.001). There was no significant differences in respect of macroscopic and microscopic scores between control, Echinacea and Echinacea-colitis groups (p > 0.3, p > 0.22). Malondialdehyde levels were elevated in colitis group compared to other groups (p < 0.001). Total antioxidant status was significantly higher in Echinacea group compared with other groups and also significantly higher in Echinacea-colitis group compared with colitis group (p < 0.001, p < 0.001, respectively). CONCLUSION: Echinacea may possibly have some therapeutic usefulness in the management of ulcerative colitis (Tab. 2, Fig. 4, Ref. 35).

Favourable effect of Eugenol on liver histology in acute cholestasis in rats after bile duct ligation.

BACKGROUND: Eugenol an essential oil found in clove was previously shown to have some anti-inflammatory properties. It also was shown to be linked to hepatoprotective effect. In this regard, we aimed to reveal the effect of eugenol on cholestatic liver disease. METHOD: Cholestatic liver disease model was established in 20 rats via bile duct ligation. Eugenol was administered and cytokine levels and liver histology after sacrifice were evaluated. RESULTS: Biliary ductular proliferation and neutropil infiltration were lower in eugenol-administered rats. CONCLUSION: Eugenol has a promising effect on liver histology in cholestatic liver disease (Tab. 1, Fig. 2, Ref. 16).

Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease.

AIM: The association between inflammatory bowel disease and pulmonary involvement has not been clearly established. The aim of this prospective study was to define the features of pulmonary function tests and high resolution computed tomography in inflammatory bowel disease patients and the relation between these and disease activity. METHOD: Fifty-two patients with inflammatory bowel disease (20 with Crohn's disease and 32 with ulcerative colitis) were enrolled. The standard pulmonary function tests and thorax high resolution computed tomography findings were investigated with respect to inflammatory bowel disease activity. Crohn's disease activity index and the Rachmilewitz endoscopic activity index for ulcerative colitis were used to assess disease activity. Medications used and smoking status were also documented. RESULTS: Among the patients with ulcerative colitis, 6.25% had an obstructive and/or restrictive ventilatory defect compared with 25% of the patients with Crohn's disease. Fifty percent of the patients with ulcerative colitis and 60% of the patients with Crohn's disease showed abnormal findings in high resolution computed tomography. Pulmonary function tests and high resolution computed tomography abnormalities did not differ significantly between Crohn's disease and ulcerative colitis. No significant difference related to inflammatory bowel disease activity was found (P > 0.05). CONCLUSION: Findings of high resolution computed tomography and the pulmonary function tests did not differ between ulcerative colitis and Crohn's disease. Bowel disease activity did not seem to affect these measurements.

Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen.

BACKGROUND: There are numerous recent reports on the use of lamivudine for hepatitis B virus (HBV) infection after renal transplantation. However, the optimal strategy (prophylactic, preemptive, or salvage approach) for starting lamivudine treatment in this patient group has not been determined. The aim of this study was to assess how the timing of lamivudine therapy affected the HBV serological status and the transaminase levels in renal allograft recipients with chronic HBV infection. METHODS: We investigated outcomes for patients who were seropositive for hepatitis B surface antigen (HBsAg) and underwent transplantation before or after October 2004 (the date our institution implemented a prophylactic lamivudine treatment strategy against HBV). The data included serum liver enzyme levels and polymerase chain reaction (PCR) screening results for HBV-DNA in serum. RESULTS: Fifteen patients (11 before October 2004, four after October 2004) were included in the study. Preoperatively all patients had normal transaminases levels and 2 of 15 patients had detectable HBV-DNA on PCR. Eight of the 15 total HBsAg-positive patients in our series were not placed on lamivudine at the time of renal transplantation. Half of those who were not treated initially showed transaminase elevations in the first year of follow-up requiring lamivudine therapy at that time. In contrast, all seven individuals who received lamivudine at the time of transplantation were negative for HBV-DNA throughout the follow-up. CONCLUSION: To prevent viral replication in HBsAg-positive patients who are scheduled for renal transplantation, it is best to initiate lamivudine therapy before or immediately after transplantation.

Hypophosphatemia in living liver donors.

BACKGROUND AND AIM: Some patients who undergo donor hepatectomy for adult living donor liver transplantation develop hypophosphatemia postoperatively. Since this imbalance appears to be a factor in postoperative complications, some authors advocate routine supratherapeutic phosphorus repletion. The purpose of this study was to determine the frequency of hypophosphatemia after elective donor lobectomy for liver transplantation and to assess whether phosphorus repletion is necessary in this patient group. METHODS: The cases of 26 patients who donated 19 right lobe and seven left lateral lobe grafts between August 2004 and March 2005 were evaluated. Postoperative phosphorus levels and other relevant data were obtained from our institution's transplant database. Presence/severity of hypophosphatemia was categorized as follows: normal (>2.5 mg/dL), mild (1.5 to 2.5 mg/dL), moderate (1.1 to 1.5 mg/dL), and profound (<1.0 mg/dL). RESULTS: No patients undergoing donor hepatectomy suffered profound or life-threatening hypophosphatemia and no donor required hyperalimentation for phosphate repletion. Twenty one donors (80.7%) did not have postoperative hypophosphatemia. In addition there appears to be no increased morbidity related to hypophosphatemia. A left lateral segment donor (3.8%) had moderate hypophosphatemia that alleviated with oral intake gradually. Four patients (15.5%; three of right lobe donor, one of left lateral segment donor) had mild hypophosphatemia. We also appropriately corrected the hypophosphatemia with encouragement of normal oral intake. By postoperative day 5, essentially all donor phosphorus levels were corrected to normal range. CONCLUSIONS: The results suggest that hypophosphatemia after donor hepatectomy is not as common as previously reported. We find that appropriate early oral intake postoperatively effectively prevents/minimizes hypophosphatemia in patients who undergo donor hepatectomy.